Top ▲

SLC51 family of steroid-derived molecule transporters C

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

Overview

Click here for help

« Hide

The SLC51 organic solute transporter family of transporters is a pair of heterodimeric proteins which regulate bile salt movements in the small intestine, bile duct, and liver, as part of the enterohepatic circulation [1-2,4]. OSTα/OSTβ is also expressed in steroidogenic cells of the brain and adrenal gland, where it may contribute to steroid sulphate movement [5]. Bile acid and steroid sulphate transport is suggested to be facilitative and independent of sodium, potassium, chloride ions or protons [2,4]. OSTα/OSTβ heterodimers have been shown to transport [3H]taurocholic acid, [3H]dehydroepiandrosterone sulphate, [3H]estrone-3-sulphate, [3H]pregnenolone sulphate and [3H]dehydroepiandrosterone sulphate[2,4-5]. OSTα/OSTβ-mediated transport is inhibited by clofazimine and fidaxomicin [8,10]. OSTα is suggested to be a seven TM protein, while OSTβ is a single TM 'ancillary' protein, both of which are thought to have intracellular C-termini [7]. Both proteins function in solute transport [3,7]. Inherited mutations in OSTα and OSTβ are associated with liver disease and congenital diarrhea in children [6,9].

Transporters

Click here for help

Targets of relevance to immunopharmacology are highlighted in blue

OSTα (Organic solute transporter subunit α / SLC51A1) C Show summary »

OSTβ (Organic solute transporter subunit β / SLC51B) C Show summary »

Further reading

Click here for help

Show »

References

Click here for help

Show »

NC-IUPHAR subcommittee and family contributors

Show »

How to cite this family page

Database page citation (select format):

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Transporters. Br J Pharmacol. 180 Suppl 2:S374-469.